Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer Patients With Intermediate/High Risk Primary Disease or Biochemical Recurrence After Treatment

NCT03444844 is registered in ClinicalTrials.gov with Five Eleven Pharma, Inc. as lead sponsor.

NCT NCT03444844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03444844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer Patients With Intermediate/High Risk Primary Disease or Biochemical Recurrence After Treatment
Lead sponsor
Five Eleven Pharma, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 10, 2018
Completion date
July 31, 2022
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, prostate cancer recurrent